AC Immune SA disclosed that Janssen has temporarily paused enrollment in the Phase 2b ReTain trial of ACI-35.030/JNJ-2056 in preclinical Alzheimer’s disease while evaluating trial aspects, including recruitment; the pause is voluntary, unrelated to safety, and the trial met its interim immunogenicity threshold without impacting liquidity. The company anticipates clinical results from other programs in 2026 and Q4 2025 earnings on March 12.
Key takeaways
Janssen temporarily paused enrollment in Phase 2b ReTain trial (NCT06544616) of ACI-35.030/JNJ-2056 while evaluating aspects including recruitment
Pause is voluntary and not related to new safety findings
Trial met pre-specified interim immunogenicity threshold
Company's capital resources sufficient into Q3 2027 excluding milestone payments
Interim 12-month ABATE trial results for ACI-24.060 expected in 2026
Phase 1 dosing for ACI-19764 to start imminently with results in H2 2026